UnknownNot Applicable

Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE

250 participantsStarted 2020-06-01

Plain-language summary

Pretransplant hepatoencephalopathy (HE) markedly impacts recipient outcomes after liver transplantation. Intraoperative CRRT showed benefits but feasibility was much concerned. This study aims to observe the effect on consciousness recovery when initiating CRRT early in the post-transplant period in recipients with ACLF and overt HE.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pre transplant liver failure: Total bilirubin over 171μmol/L and prothrombin activity (PTA)\<40%;
✓. Overt hepatic encephalopathy(HE): Grade II or higher HE according West Haven classification;
✓. HE associated with acute liver failure (Type A) or cirrhosis complicated with portal hypertension and/or portal systemic shunts (Type C)

Exclusion criteria

✕. Patients with a previous history of kidney-related diseases and glomerular filtration rate \<30 millilitre per minute;
✕. Patients with acute renal failure need CRRT before transplantation;
✕. Patients newly developed acute renal failure need CRRT at the time of randomization;
✕. Retransplantation or multiple-organs transplantation;
✕. Any ischemic or hemorrhagic stroke co-morbidity;
✕. Hemodynamic instability requiring fluid resuscitation or very high dose of vasopressors;
✕. Extremely moribund patients with an expected life expectancy of less than 24 hours.

What they're measuring

Consciousness recovery time

Timeframe: From the immediate to 30 days after liver transplantation

Adverse events

Timeframe: From the immediate to 7 days after liver transplantation (CRRT therapy period)

Trial details

NCT IDNCT04317222

SponsorThird Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-31

Contact for this trial

Huimin Yi, doctor

18922102510 ylhmin@hotmail.com

View on ClinicalTrials.gov More Acute-On-Chronic Liver Failure trials